RayKnowChina Research Map
Shortlist

Xi'an

Shaanxi Provincial People's Hospital

陕西省人民医院

Listed for 9 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shaanxi Provincial People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  2. Stomach cancer胃癌27 papers led
  3. Breast cancer乳腺癌18 papers led
  4. Retinoblastoma视网膜母细胞瘤0 papers led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Neuroblastoma神经母细胞瘤2 papers led
  7. Multiple myeloma多发性骨髓瘤3 papers led
  8. Coronary heart disease冠心病16 papers led1 open trial led
  9. Congenital heart disease先天性心脏病3 papers led

Not listed for: Nasopharyngeal carcinoma, Hepatocellular carcinoma, Lung cancer, Pancreatic cancer, Glioma, Hepatoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

5 hospitals in Xi'an for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led3
  1. Tumor-derived exosomal hyaluronidase 1 induced M2 macrophage polarization and promoted esophageal cancer progression.2024Experimental cell research
  2. Patterns and prognostic predictive value of perineural invasion in esophageal squamous cell carcinoma.2022BMC cancerFree full text
  3. The role of vascular invasion and lymphatic invasion in predicting recurrent thoracic oesophageal squamous cell carcinoma.2022World journal of surgical oncologyFree full text
More papers found outside PubMed (not counted)6
  1. The impact of lymph node resection and survival prediction by machine learning in esophageal squamous cell carcinoma patients over 60 years old: a clinical trial based on the SEER database and Chinese population2025Research Squarepreprint
  2. Tumor marker index based on CYFRA21-1 and NSE is an important screening index for early-stage esophageal squamous cell carcinoma high-risk groups2023Research Squarepreprint
  3. 165. DIVERSITY OF PERINEURAL INVASION AND THEIR PREDICTIVE ROLE IN PROGNOSIS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  4. 167. LYMPHATIC INVASION CAN PREDICT POSTOPERATIVE LYMPH NODE RECURRENCE IN PATIENTS WITH ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  5. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  6. Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 27 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 101020222023: 4420232024: 7720242025: 442025

5 hospitals in Xi'an for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseSurgeryImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyPathology / laboratory medicine
Papers it led27
  1. CT Radiomics for Predicting Outcomes in HER2-Positive Surgically Resectable Advanced Gastric Cancer: A Preliminary Study.2025Academic radiology
  2. Oleandrin Promotes Apoptosis in an Autophagy-Dependent Manner in Gastric Cancer.2025Frontiers in bioscience (Landmark edition)
  3. RBM8A promotes gastric cancer progression by binding with UPF3B to induce BBC3 mRNA degradation.2025International journal of molecular medicineFree full text
  4. INHBA, transcriptionally activated by SPI1, facilitates gastric cancer progression by inducing macrophage recruitment and M2 polarization via activating the TGF-β signaling to increase CCL2.2025Pathology, research and practice
  5. The value of the radiological diameter-to-thickness ratio in patients with HER2-positive resectable advanced gastric cancer: implications for long survival and stage migration.2024Abdominal radiology (New York)
  6. Risk factor analysis and establishment of a predictive model for complications of elderly advanced gastric cancer with Clavien-Dindo classification ≥ II grade.2024BMC cancerFree full text
  7. Gastric cancer cell-derived exosomal miR-541-5p induces M2 macrophage polarization through DUSP3/JAK2/STAT3 pathway.2024BMC cancerFree full text
  8. Rhaponticin suppresses the stemness phenotype of gastric cancer stem-like cells CD133+/CD166 + by inhibiting programmed death-ligand 1.2024BMC gastroenterologyFree full text
  9. Comparison of proximal gastrectomy with tubular esophagogastric anastomosis and total gastrectomy with Roux-en-Y reconstruction in the treatment of adenocarcinoma of the esophagogastric junction of Siewert type II/III at stage II.2024BMC surgeryFree full text
  10. Helicobacter pylori induce circ_0046854 to regulate microRNA-511-3p/CSF1 axis and enhance the resistance of gastric cancer to cisplatin.2024Journal of biochemical and molecular toxicology
  11. Polyhedral magnetic nanoparticles induce apoptosis in gastric cancer stem cells and suppressing tumor growth through magnetic force generation.2024Journal of controlled release : official journal of the Controlled Release Society
  12. Development and external validation of a non-invasive imaging biomarker to estimate the microsatellite instability status of gastric cancer and its prognostic value: The combination of clinical and quantitative CT-imaging features.2023European journal of radiology
  13. Immune checkpoint inhibitors are effective in the treatment of Epstein-Barr virus-associated gastric cancer: A case report.2023MedicineFree full text
  14. Safety and efficacy of indocyanine green near-infrared fluorescent imaging-guided lymph node dissection during robotic gastrectomy for gastric cancer: a systematic review and meta-analysis.2023Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  15. Evaluation of Fourier transform infrared (FTIR) spectroscopy with multivariate analysis as a novel diagnostic tool for lymph node metastasis in gastric cancer.2023Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  16. Does the LHPP gene share a common biological function in pancancer progression?2022BMC medical genomicsFree full text
  17. LncRNA LINC02253 activates KRT18/MAPK/ERK pathway by mediating N6-methyladenosine modification of KRT18 mRNA in gastric cancer.2022Carcinogenesis
  18. Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer.2022Disease markersFree full text
  19. GBAP1 polymorphisms (rs140081212, rs1057941 and rs2990220) contribute to reduced risk of gastric cancer.2022Future oncology (London, England)
  20. Safety and effectiveness of overlap esophagojejunostomy in totally laparoscopic total gastrectomy for gastric cancer: A systematic review and meta-analysis.2022International journal of surgery (London, England)
  21. Novel classification and risk model based on ferroptosis-related lncRNAs to predict oncologic outcomes for gastric cancer patients.2022Journal of biochemical and molecular toxicology
  22. Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal-epithelial transition factor (MET): A case report.2022MedicineFree full text
  23. KAT7 promoted gastric cancer progression through promoting YAP1 activation.2022Pathology, research and practice
  24. Clinical significance of controlling nutritional status score (CONUT) in evaluating outcome of postoperative patients with gastric cancer.2022Scientific reportsFree full text
  25. Machine learning-based gray-level co-occurrence matrix signature for predicting lymph node metastasis in undifferentiated-type early gastric cancer.2022World journal of gastroenterologyFree full text
  26. JHDM1D-AS1 aggravates the development of gastric cancer through miR-450a-2-3p-PRAF2 axis.2021Life sciences
  27. Naringin induces apoptosis of gastric carcinoma cells via blocking the PI3K/AKT pathway and activating pro‑death autophagy.2021Molecular medicine reportsFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  3. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 18 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 3320212022: 6620222023: 0020232024: 5520242025: 332025

8 hospitals in Xi'an for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06790693

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang

  2. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led18
  1. Investigating the causality and pathogenesis of multiple sclerosis in breast cancer via bioinformatics analysis.2026Multiple sclerosis and related disorders
  2. Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer.2025BMC cancerFree full text
  3. An injectable hydrogel for hemostasis and tumor suppression in intraoperative breast cancer.2025Biomaterials advances
  4. Computational Analysis of Exosome-Derived Signature in TNBC: Integrating Single-Cell and Bulk Transcriptomics for Prognosis Prediction.2025Clinical and translational scienceFree full text
  5. Identifying the mechanism of polysaccharopeptide against breast cancer based on network pharmacology and experimental verification.2024BMC cancerFree full text
  6. Development and Validation of a Nomogram for Prognosis Prediction in Patients with Synchronous Primary Thyroid and Breast Cancer Based on SEER Database.2024Cancer investigation
  7. Interactions between the tumor microbiota and breast cancer.2024Frontiers in cellular and infection microbiologyFree full text
  8. Who can benefit from postmastectomy radiotherapy among HR+/HER2- T1-2 N1M0 breast cancer patients? An explainable machine learning mortality prediction based approach.2024Frontiers in endocrinologyFree full text
  9. Comprehensive Molecular Analyses of an M2-Like Tumor-Associated Macrophage for Predicting the Prognosis and Immunotherapy in Breast Cancer.2024Journal of immunotherapy (Hagerstown, Md. : 1997)
  10. Perceived needs and health-related quality of life in women with breast cancer undergoing chemotherapy: a cross-sectional study.2022BMJ openFree full text
  11. Advanced glycation end products correlate with breast cancer metastasis by activating RAGE/TLR4 signaling.2022BMJ open diabetes research & careFree full text
  12. Construction of a Prognostic Nomogram Model for Patients with Mucinous Breast Cancer.2022Journal of healthcare engineeringFree full text
  13. REC8 inhibits proliferation, migration and invasion of breast cancer cells by targeting CDC20.2022Molecular medicine reportsFree full text
  14. Necroptosis-related lncRNA signatures determine prognosis in breast cancer patients.2022Scientific reportsFree full text
  15. The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway.2022Toxicology and applied pharmacology
  16. CASC15 Polymorphisms are Correlated With Breast Cancer Susceptibility in Chinese Han Women.2021Clinical breast cancer
  17. Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  18. Effects of miR‑93 on epithelial‑to‑mesenchymal transition and vasculogenic mimicry in triple‑negative breast cancer cells.2021Molecular medicine reportsFree full text
All its trials on ClinicalTrials.gov, any status4
  1. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Study sitePhase 2/Phase 3Start 2025-06
  2. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruitingNCT06790693Study sitePhase 3Start 2025-04
  3. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  4. A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerActive, not recruitingNCT05132582Study sitePhase 3Start 2022-03

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Xi'an for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

11 hospitals in Xi'an for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

12 hospitals in Xi'an for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

4 hospitals in Xi'an for multiple myeloma175 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesBispecific & antibody drugs
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 16 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.3%.

Papers led
16
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 1120222023: 3320232024: 2220242025: 552025

5 hospitals in Xi'an for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Coronary Arterial Microcirculation and Metabolism
    Phase
    Not given
    Started
    2025-02
    Posted
    Registry
    NCT07074847

    Age 18 years to 80 years (registered criteria)

    Led by Shaanxi Provincial People's HospitalXi'an

  2. Recruiting
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07521007

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology
Papers it led16
  1. Prospective, multicenter, randomized controlled study on the efficacy and safety of intravascular ultrasound-guided drug-coated balloon for de novo small-vessel coronary lesions: Design and rationale of the DCB-IVUS trial.2026American heart journal
  2. Nε-carboxyethyl-lysin influences atherosclerotic plaque stability through ZKSCAN3 acetylation-regulated macrophage autophagy via the RAGE/LKB1/AMPK1/SIRT1 pathway.2025Cardiovascular diabetologyFree full text
  3. Matrine alleviates coronary microvascular dysfunction in ischemia with non-obstructive coronary artery disease mice induced by advanced glycation end products inhibition of the reactive oxygen species-mediated endoplasmic reticulum stress i2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  4. Risk Factors for Comorbid Anxiety in Patients with Coronary Heart Disease and Association with Noise Exposure.2025Noise & healthFree full text
  5. Genetic insights into circulating osteocalcin for cardiovascular diseases and the role of vascular calcification.2025Nutrition, metabolism, and cardiovascular diseases : NMCD
  6. Adenosine stress myocardial perfusion imaging and myocardial work in evaluating INOCA.2025Scientific reportsFree full text
  7. The effect of vitamin D status on the occurrence of Kawasaki Disease: a meta-analysis.2024BMC pediatricsFree full text
  8. Diagnostic performance of the quantitative flow ratio and CT-FFR for coronary lesion-specific ischemia.2024Scientific reportsFree full text
  9. Gelanxinning capsule improves coronary microvascular dysfunction by inhibiting inflammation and restoring endothelial function.2023European review for medical and pharmacological sciencesRCT
  10. Circulating levels of cytokines and risk of cardiovascular disease: a Mendelian randomization study.2023Frontiers in immunologyFree full text
  11. Very early onset of coronary artery aneurysm in a 3-month infant with Kawasaki disease: a case report and literature review.2023Italian journal of pediatricsFree full text
  12. Integrated analysis of miRNA-mRNA regulatory network and functional verification of miR-338-3p in coronary heart disease.2022Functional & integrative genomics
  13. The usefulness of subtraction coronary computed tomography angiography for in-stent restenosis assessment of patients with CoCr stent using 320-row area detector CT.2021MedicineFree full text
  14. AGEs exacerbates coronary microvascular dysfunction in NoCAD by activating endoplasmic reticulum stress-mediated PERK signaling pathway.2021Metabolism: clinical and experimental
  15. Analysis of the association and predictive value of hyperhomocysteinaemia for obstructive coronary artery disease.2021The Journal of international medical researchFree full text
  16. Relationship between serum cystatin-c and coronary lesion severity in coronary artery disease patients with a normal glomerular filtration rate.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)3
  1. [Clinical experience in the treatment of incomplete Kawasaki disease with no response to intravenous immunoglobulin: a case report].2022Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
  2. [A case of right auricle and right coronary artery perforation caused by active pacing electrodes].2022Zhonghua xin xue guan bing za zhi
  3. [Interpretation of the JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease].2021Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatricsFree full text
All its trials on ClinicalTrials.gov, any status6
  1. Coronary Arterial Microcirculation and MetabolismEnrolling by invitationNCT07074847Lead sponsorStart 2025-02
  2. Plaque Stability and Metabolomics in Coronary Heart DiseaseStatus unknownNCT05270330Lead sponsorStart 2021-07
  3. Clinical Observation of Coronary Arterial Microcirculation Dysfunction in Diabetic Patients With Non- Obstructive Coronary Artery DiseaseStatus unknownNCT02748980Lead sponsorStart 2016-03
  4. Frank Score and Coronary Artery DiseaseCompletedNCT03177486Lead sponsorStart 2015-12
  5. A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisRecruitingNCT07521007Study sitePhase 2Start 2026-07
  6. Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)CompletedNCT04624854Study sitePhase 4Start 2020-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 3 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

6 hospitals in Xi'an for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

陕西省人民医院

Shaanxi Provincial People's Hospital

西安

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Third Affiliated Hospital (Shaanxi Provincial People's Hospital); Affiliated Shaanxi Provincial People's Hospital; Shaanxi Provincial Peoples Hospital; Shaanxi Provincial People'S Hospital; Third Affiliated Hospital of Xi'an Jiaotong University

Suggest a correctionDownload the data